 After completion of induction therapy, patients undergo risk assessment. Patients with M1 marrow and minimal residual disease MRD 1 defined as low- and intermediate-risk proceed to consolidation therapy at day 36 or when blood counts recover whichever occurs later. Patients with M2 marrow 5-25 blasts andor MRD 1 defined as high-risk proceed to consolidation therapy as soon as possible i.e., they should not wait until day 36 or for blood counts to recover. Patients with M3 marrow 25 blasts defined as induction failure proceed to consolidation therapy as soon as possible. 